Gain detailed insights into the trading activity of Congress members for Healthpeak Properties on our government trades page. Stay updated on how elected officials are investing in DOC.

Healthpeak Properties - Government Trades

Healthpeak Properties

Physicians Realty Trust

Healthpeak owns a diversified healthcare portfolio of approximately 748 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.

Earnings

News

Markets

Analyst Ratings

Trading Ideas

AGNC

Wall Street watches a company&#39;s quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.

These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar

Miniature,Wooden,Houses,And,A,Green,Arrow,Down.,The,Concept

REIT

Real Estate

7 REITs Receive Analyst Upgrades In The First Week Of May

ALEX

REXR

3 REITs That Just Raised 2024 Full-Year Guidance

Buy,Or,Sell,Buttons,Concept.,Close,Up,Computer,Screen,View

AMZN

Analysts Just Upgraded These 4 REITs

Short Ideas

Small Cap

Pre-Market Outlook

CHCI

As of April 4, 2024, three stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Real Estate Stocks That Are Ticking Portfolio Bombs

Reit,Real,Estate,Investment,Trust,Symbol.,Concept,Words,Reit,Real

PEAK

SITC

STAG

2024&#39;s Rough Start: More Than A Half Dozen REITs Get Downgrades

General

GOOG

GOOGL

HSBC

PCRFY

RIVN

Penalty Warranted For Southwest Airlines&#39; Flight Fiasco, Amazon Leverages Generative AI for Holiday Ad Boost, McDonald&#39;s Q3 Earnings: Today&#39;s Top Stories

Large Cap

Health Care

Movers

Healthpeak Properties Inc (NYSE: PEAK) and Physicians Realty Trust (NYSE: DOC) have agreed to merge in an all-stock merger of equals valued at 

Healthcare Property Firms Healthpeak Properties And Physicians Realty Trust To Merge In $21B Deal

Modern,Hospital,Style,Building

$LTC

CTRE

SBRA

WELL

Analysts: Healthcare REITs Show A Dichotomy Of Performance

Dividends

Price Target

GMRE

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a  high dividend payout. 

Check Out 3 Real Estate Stocks With Over 6% Dividend Yields From Wall Street&#39;s Most Accurate Analysts

Healthpeak Properties Inc

Dock - United States Dollar

BEYOND MED TECHS INC by BEYOND MED TECHNOLOGIES INC.

Beyond Medical Technologies Inc

Dr. Martens PLC

DigitalOcean Holdings Inc

Docola, Inc

CLOUDMD SOFTWARE & SVCS by CloudMD Software & Services Inc.

CloudMD Software & Services Inc

Doximity Inc

FT Vest U.S. Equity Deep Buffer ETF - October

DocuSign Inc

<p>Analysts' ratings for Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Healthpeak Properties and provided 12-month price targets. The average target is $21.86, accompanied by a high estimate of $25.00 and a low estimate of $19.00. Witnessing a positive shift, the current average has risen by 9.3% from the previous average price target of $20.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715868023_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Healthpeak Properties. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Healthpeak Properties. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Healthpeak Properties's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Healthpeak Properties's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Healthpeak Properties analyst ratings.</strong></a></p>
<h2>About Healthpeak Properties</h2>
<p>Healthpeak owns a diversified healthcare portfolio of approximately 459 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.</p>
<h3>Healthpeak Properties's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Healthpeak Properties showcased positive performance, achieving a revenue growth rate of <strong>15.65%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.</p>
<p><strong>Net Margin:</strong> Healthpeak Properties's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>1.08%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Healthpeak Properties's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.08%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Healthpeak Properties's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.04%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.02</strong>, Healthpeak Properties adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For Healthpeak Properties

<p>Scotiabank  analyst Nicholas Yulico   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Sector Outperform and raises the price target from $22 to $23.</p>


Scotiabank Maintains Sector Outperform on Healthpeak Properties, Raises Price Target to $23

<p>JP Morgan  analyst Michael Mueller   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Neutral and raises the price target from $19 to $21.</p>


JP Morgan Maintains Neutral on Healthpeak Properties, Raises Price Target to $21

<p>Analyst upgrades are always welcome news for investors because upgrades trigger buying activity which supports share price appreciation.</p>
<p>It looks like Analysts are feeling better about the future direction of interest rates and interest-sensitive stocks such as real estate investment trusts (REITs) because, this week, seven different REITs across five different subsectors have received analyst upgrades.</p>
<p><strong>Sunstone Hotel Investors Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) is an Aliso Viejo, CA-based Hotel REIT with 6675 rooms in 14 hotels, on both U.S. coasts and Hawaii. Its hotel brands include Hyatt Regency, Marriott, Hilton, and Four Seasons.</p>
<p>On May 8, Sunstone Hotel Investors reported its first quarter 2024 operating results. Funds from Operation (FFO) of $0.19 per share beat the estimate of $0.17 per share but was below $0.21 per share FFO in Q1 2023. Revenue of $217.166 million was ahead of the estimate of $214.595 million but below revenue of $243.443 million in Q1 2023.</p>
<p>Disregarding the decreases from the year-ago period, On May 7, Compass Point analyst Floris Van Dijkum upgraded Sunstone Hotel from Sell to Neutral and raised the price target from $10 to $12.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li>Only 0.2% of single-family rentals make this platform's rigorous cut. You can co-invest in them <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">with Jeff Bezos and other notable investors for only $100</a>.</li>
<li>New York is the second financial capital in the US' history. Now a third one is emerging and <a href="https://www.benzinga.com/money/cityfunds-yield">investing in its booming real estate market</a> takes as little as $500 and a few clicks. </li>
</ul>
<p><strong>Camden Property Trust </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>)<strong> </strong>is a Houston, TX-based residential REIT that owns and manages 172 properties with 58,634 units in 15 major cities across the U.S. Some apartment complexes also contain ground-floor retail space, offices, or mixed-use space. It's a member of the Standard &amp; Poor&#8217;s 500 index (S&amp;P 500 and) and had its IPO in 1993. At the end of Q3 2023, its occupancy level was 95.0%.</p>
<p>On May 6, Piper Sandler analyst Alexander Goldfarb upgraded Camden Property Trust from Underweight to Neutral and raised the price target from $90 to $110. Three other Brokerages maintained previous positions on the same day, with all raising price targets between $110 and $118.</p>
<p><strong>Mid-America Apartment Communities Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) is a self-administered residential REIT specializing in purchasing and leasing apartment complexes. As of March 2024, it owns 102,662 units in 300 communities across 16 states and Washington, D.C. Most Mid-America Apartment Communities' properties are in the Southeast, Southwest, and mid-Atlantic states.</p>
<p>On May 1, Mid-America reported its Q1 2024 operating results. FFO of $2.22 was in line with estimates but was below FFO of $2.28 from Q1 2023. Revenue of $543.62 million beat the estimate of $542.72 million and was above Q1 2023 revenue of $529.03 million.</p>
<p>On May 6, Wedbush analyst Richard Anderson upgraded Mid-America Apartment from Neutral to Outperform, raising the price target by 14% from $135 to $154.<strong>&nbsp;</strong></p>
<p><strong>&nbsp;</strong><strong>Trending:</strong></p>
<ul>
<li>Elon Musk, Ken Griffin and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US. <a href="https://www.benzinga.com/money/cityfunds-yield">Investing in its booming real estate market has never been more accessible</a>. </li>
</ul>
<p><strong>Healthpeak Properties Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is an El Segundo, CA-based diversified health care REIT that owns and operates private-pay facilities such as life science centers, medical offices, and continuing care retirement communities. Although it has properties throughout the country, most are in the San Francisco, San Diego, and Boston areas. Healthpeak's IPO was created in 1985 and was added to the S&amp;P 500 in 2008. It presently owns 774 properties worth over $20 billion.</p>
<p>On March 1, Healthpeak officially merged with Physicians Realty Trust in an all-stock-for-stock transaction.&nbsp;</p>
<p>On April 25, Healthpeak reported its first quarter 2024 operating results. FFO of $0.45 per share was a penny above the consensus estimate and a 7.14% increase over FFO of $0.42 per share in Q1 2023. Revenue of $606.560 million topped the consensus estimate of $588.284 million and was a 15.39% increase over revenue of $525.678 million in Q1 2023.</p>
<p>Healthpeak also announced an increase in its FY24 Diluted Adjusted Funds From Operations (AFFO) Guidance from $1.50-$1.56 to $1.53-$1.57.&nbsp;</p>
<p>Investors cheered the news and Healthpeak rose over 2% following its earnings and guidance release.</p>
<p>On May 3, Wedbush analyst Richard Anderson upgraded Healthpeak Properties from Neutral to Outperform. No price target was given.</p>
<p><strong>Tanger Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>), formerly called <strong>Tanger Factory Outlet Centers Inc</strong>, is a Greensboro, NC-based retail REIT that owns, co-owns, or manages 40 indoor shopping centers and outdoor factory outlet malls with 15.6 million square feet and over 3000 stores across 20 states and in Canada. Tanger Factory Outlet Centers was founded in 1981 and had its IPO in May 1993. Tanger's occupancy rate at the end of 2023 was 97.3%</p>
<p>On April 30, Tanger reported excellent first quarter operating results. FFO of $0.52 beat the estimate of $0.51 and topped its Q1 2023 FFO of $0.46 per share. Revenue of $123.371 million beat the estimate of $122.804 million and was 13.24% above revenue from Q4 2022 of $108.943 million. Tanger also raised its Full Year 2024 Core FFO from $2.01-$2.09 per share to $2.03-$2.11.<strong>&nbsp;</strong></p>
<p>On May 2, Compass Point analyst Floris Van Dijkum upgraded Tanger from Neutral to Buy and announced a price target of $32.</p>
<p><strong>PotlatchDeltic Corp </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) is a specialty REIT that invests in timberland. The Spokane, WA-based company owns nearly 2.2 million acres of timberlands across seven states. It was founded in the year 1903 as Clearwater Timber Company and became a REIT in 2006. PotlatchDeltic merged with CatchMark Timer Trust, Inc. in 2022.</p>
<p>On April 29, PotlatchDeltic released its first quarter 2024 operating results. Non-GAAP EPS of $0.00 beat the estimates of (0.02). Revenue of $228.127 million was ahead of the consensus estimate of $227.841 million and was 11.57% below its Q1 2023 revenue of $257.962 million.</p>
<p>On May 1, RBC Capital analyst Matthew McKellar upgraded PotlatchDeltic from Sector Perform to Outperform and announced a $46 price target.</p>
<p><strong>American Tower Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) is a Boston, MA-based specialty REIT that calls itself "a global leader in wireless infrastructure." Founded in 1995, American Tower owns, operates, and develops wireless and broadcast communications real estate. Most of its business is leasing space on wireless and broadcast towers and it also leases portions of the land below the tower for equipment storage. Typical tower components are coaxial cabling and fiber optic cables.</p>
<p>American Tower has a presence in 224,000 global communication sites across 25 different countries in six continents. About 42,000 of those properties are in the U.S. and Canada, and approximately 181,000 are international properties</p>
<p>On April 30, American Tower released its first quarter 2024 operating results. Adjusted Funds from Operations (AFFO) of $2.79 per share easily beat the consensus estimate of $2.54 per share, and AFFO of $2.54 in Q1 2023. Revenue of $2.834 billion also beat the street's view of $2.795 billion and topped revenue of $2.767 billion from Q1 2023.</p>
<p>On May 1, Raymond James analyst Ric Prentiss upgraded American Tower from Outperform to Strong Buy and raised the price target from $226 to $248.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/real-estate/23/05/32554601/want-to-grow-your-wealth-passively-these-high-yield-real-estate-notes-might-be-your-holy-grail">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/money/dara-khosrowshahi-backed-startup-lets-you-become-a-landlord-with-100">Become a Landlord with $100</a>.</li>
</ul>


<p>Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) ("Healthpeak") and King Street Properties ("KSP") today announced that Healthpeak has acquired KSP's minority interest in the joint ventures in eight lab buildings in Cambridge and Lexington, Massachusetts. Healthpeak will assume day-to-day management of the buildings following a short-term transition period.</p>
<p>"King Street has been a key strategic partner of Healthpeak's since 2017," said Scott Brinker, Healthpeak's President and CEO. "Our successful partnership grew to 900,000 square feet across four campuses." Mr. Brinker continued, "Healthpeak's greater Boston portfolio now totals 2.7 million square feet, giving us the scale to internalize. We would like to thank the KSP team for many years of outstanding partnership and mutual success."</p>
<p>"Seven years ago, we and Healthpeak formed a joint venture to maximize the development potential of a portion of King Street's Boston portfolio of Class A life science projects," said Thomas Ragno, King Street's Founder/Principal. "We enjoyed working with the Healthpeak team to meet that goal and today marks the culmination of this innovative approach, which has proven to be highly successful for both firms."</p>


Healthpeak Properties Has Acquired KSP's Minority Interest In The Joint Ventures In Eight Lab Buildings In Cambridge And Lexington, Massachusetts; No Financial Terms Disclosed

<p>Wedbush  analyst Richard Anderson   upgrades Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) from Neutral to Outperform.</p>


Upgrades

Wedbush Upgrades Healthpeak Properties to Outperform

<p>Earnings are crucial for the share price of a stock to appreciate. But often, even good earnings fail to lift a stock if a company's forward guidance is weaker than analysts expect. <strong>Prologis Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) investors recently found this out as its shares were hit hard following the announcement that while core funds from operations (FFO) matched estimates, Prologis had revised full-year 2024 core FFO lower. Prologis subsequently lost almost 10% within a week.</p>
<p>Investors must also look at forward guidance plus the previous quarter's earnings when assessing stocks for possible purchase or sale. With that in mind, take a look at three real estate investment trusts (REITs) that recently raised full-year 2024 forward guidance from previous levels.<br /></p>
<p><strong>Alexander &amp; Baldwin Inc. (Hawaii) </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALEX#NYSE">ALEX</a>) is a Honolulu-based diversified REIT exclusively focused on Hawaii commercial real estate. Alexander &amp; Baldwin owns and operates 22 retail centers, 13 industrial assets and four office properties with 3.9 million square feet. It also has 142 acres of ground-lease assets. Its leased occupancy as of March 31 was 94%. The company has a 154-year history of operation.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
<p>On April 25, Alexander reported its first-quarter 2024 operating results. FFO of $0.35 beat the consensus of $0.26 and topped FFO of $0.29 in the first quarter of 2023. Revenue of $61.2 million beat the estimates of $49.25 million and first-quarter 2023 revenue of $50.4 million.</p>
<p>More significantly, Alexander &amp; Baldwin also raised its full-year 2024 adjusted funds from operations (AFFO) guidance from $0.80-$0.90 to $0.89-$1.00.</p>
<p>Piper Sandler analyst Alexander Goldfarb recently maintained a Neutral rating on Alexander &amp; Baldwin, with a $17 price target. Its recent closing price was $15.83, but it opened about 3% higher the morning following the earnings and guidance call.</p>
<p><strong>Healthpeak Properties Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is an El Segundo, California-based diversified healthcare REIT that owns and operates private-pay facilities such as life science centers, medical offices and continuing care retirement communities. Although it has properties across the U.S., most are in the San Francisco, San Diego and Boston areas. Healthpeak's initial public offering (IPO) launched in 1985, and the company was added to the S&amp;P 500 in 2008. It owns 774 properties worth over $20 billion.</p>
<p>On March 1, Healthpeak officially merged with Physicians Realty Trust in an all-stock-for-stock transaction. Physicians Realty Trust's PEAK symbol was changed to DOC.</p>
<p><strong>Trending:</strong></p>
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>
<p>On April 1, Bank of America Securities analyst Joshua Dennerlein upgraded Healthpeak Properties from Underperform to Buy and raised the price target 38.8% from $18 to $25.</p>
<p>On April 25, Healthpeak reported its first-quarter 2024 operating results. FFO of $0.45 per share was a penny above the consensus estimate and a 7.14% increase over FFO of $0.42 per share in the first quarter of 2023. Revenue of $606.56 million topped the consensus estimate of $588.284 million and was a 15.39% increase over revenue of $525.678 million in the first quarter of 2023.</p>
<p>Healthpeak also announced an increase to its full-year 2024 diluted AFFO guidance from $1.50-$1.56 to $1.53-$1.57.</p>
<p>Investors cheered the news and Healthpeak rose over 2% the morning following its earnings and guidance release.</p>
<p><strong>Rexford Industrial Realty Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) is a Los Angeles-based industrial REIT with 422 properties totaling 49 million square feet that it owns or manages, primarily in Southern California's high-growth areas. Rexford Industrial is a member of the S&amp;P 400 and was founded in 2001. Rexford's first-quarter occupancy rate was 96.8%.</p>
<p>On April 16, Truist Securities analyst Anthony Hau maintained a Buy rating on Rexford Industrial Realty but lowered the price target from $57 to $53.</p>
<p>On April 17, Rexford Industrial Realty<strong> </strong>reported its first-quarter 2024 operating results. FFO of $0.58 per share beat the analyst consensus estimate of $0.57. Revenue of $210.99 million missed the consensus estimate of $211.56 million and was a 13.95% improvement over $185.16 million in revenue during the first quarter of 2023.</p>
<p>Unlike its peer Prologis, Rexford raised its full-year 2024 core FFO of $2.27-$2.30 per share to $2.31-$2.34. Although Rexford did not initially benefit much in share price, largely because of the sympathy selling of industrial REITs along with Prologis, it has been climbing higher over the past few days.&nbsp;</p>
<p><strong>Read Next:</strong></p>
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
</ul>


WIIM

Healthpeak Properties shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY24 guidance.

Guidance

Healthpeak Properties Raises FY24 Diluted AFFO Guidance From $1.50–$1.56 To $1.53–$1.57

<p>Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.44 by 2.27 percent. This is a 7.14 percent increase over earnings of $0.42 per share from the same period last year.  The company reported quarterly sales of $606.560 million which beat the analyst consensus estimate of $588.284 million by 3.11 percent.  This is a 15.39 percent increase over sales of $525.678 million the same period last year.</p>


Earnings Beats

Healthpeak Properties Q1 2024 FFO $0.45 Beats $0.44 Estimate, Sales $606.560M Beat $588.284M Estimate

<p>Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.8, a high estimate of $25.00, and a low estimate of $19.00. Surpassing the previous average price target of $19.50, the current average has increased by 11.79%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713794456_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Healthpeak Properties is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Healthpeak Properties. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Healthpeak Properties's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Healthpeak Properties's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Healthpeak Properties analyst ratings.</strong></a></p>
<h2>All You Need to Know About Healthpeak Properties</h2>
<p>Healthpeak owns a diversified healthcare portfolio of approximately 459 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.</p>
<h3>Healthpeak Properties: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Healthpeak Properties's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>5.56%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Healthpeak Properties's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>12.79%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.11%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Healthpeak Properties's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.45%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Healthpeak Properties's debt-to-equity ratio is below the industry average at <strong>1.12</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Healthpeak Properties Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p>Mizuho  analyst Omotayo Okusanya   reinstates Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Buy and announces $22 price target.</p>


Initiation

Mizuho Reinstates Buy on Healthpeak Properties, Announces $22 Price Target

<p>RBC Capital  analyst Michael Carroll   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $21 to $22.</p>


RBC Capital Maintains Outperform on Healthpeak Properties, Raises Price Target to $22

<p>The start of the second quarter of 2024 has been challenging for real estate investment trusts (REITs). On Good Friday, when Federal Reserve Chairman Jerome Powell noted that higher-than-expected strength in job gains and inflation may delay or reduce interest rate cuts in 2024, markets again sold off interest rate-sensitive stocks such as REITs.</p>
<p>Despite the latest disappointment, there was some good news last week, as analysts upgraded several REITs and raised price targets on many others while still maintaining previous ratings.</p>
<p>Take a look at four REITs that analysts at Bank of America Securities recently upgraded.</p>
<p><strong>Tanger Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>), formerly <strong>Tanger Factory Outlet Centers Inc.</strong>, is a Greensboro, North Carolina-based retail REIT that owns 40 indoor shopping centers and outdoor factory outlet malls with 15.6 million square feet and over 3,000 stores across 20 states and Canada. Tanger Factory Outlet Centers was founded in 1981 and had its initial public offering (IPO) in May 1993. Tanger's occupancy rate at the end of 2023 was 97.3%.&nbsp;</p>
<p>On Feb. 15, Tanger reported excellent fourth-quarter operating results. Funds from operations (FFO) of $0.52 beat the estimate of $0.50. Revenue of $127.48 million beat the estimate of $119.04 million and was 9.46% above revenue from the fourth quarter of 2022 of $116.46 million. Additionally, full-year core FFO was announced in a range from $2.01-$2.09 per share, with a midpoint above the analyst consensus estimate of $2.03 per share.</p>
<p>Tanger was the second-leading REIT overall in 2023, with a total return of 63.58%, negating the popular notion that in-store retail shopping has lost out to <strong>Amazon.com Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and other online websites.</p>
<p>On April 5, Bank of America Securities analyst Jeffrey Spector upgraded Tanger from Underperform to Neutral and raised the price target 29.1% from $24 to $31. On March 22, Citigroup analyst Michael Bilerman also upgraded Tanger from Neutral to Buy and raised the price target from $30 to $33.&nbsp;&nbsp;&nbsp;</p>
<p><strong>Acadia Realty Trust </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) is a Rye, New York-based retail REIT with 189 properties (as of the fourth quarter of 2023) across centralized urban areas in 22 states and Washington, D.C. The overall lease rate is approximately 95% with annual rent increases of 3%.</p>
<p>On April 5, Bank of America Securities analyst Craig Schmidt upgraded Acadia Realty Trust from Neutral to Buy and raised the price target by 11.1% from $18 to $20. This upgrade could not have come at a better time, as many retail REITs, including Acadia Realty, were getting hit hard last week following Powell's remarks.</p>
<p>Acadia will announce its first-quarter 2024 earnings on April 29.&nbsp;</p>
<p><strong>Essex Property Trust Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) is a residential REIT that owns and operates 252 apartment communities with 62,000 units in the West Coast states of California and Washington. Essex Property Trust is a member of the S&amp;P 500 and a Dividend Aristocrat.&nbsp;</p>
<p>On March 25, Essex Property Trust acquired JV Partner's 49.9% interest in four apartment communities, with 1,480 units for a total purchase price of $505 million.&nbsp;</p>
<p>On April 1, Bank of America Securities analyst Joshua Dennerlein upgraded Essex Property Trust from Neutral to Buy and raised the price target by 10% from $250 to $275.</p>
<p>Analyst price targets vary widely. Within the past two weeks, Truist Securities has maintained a Hold on Essex with a $259 price target, and Piper Sandler has maintained an Overweight position and a $291 price target.<strong>&nbsp;</strong></p>
<p><strong>Healthpeak Properties Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is an El Segundo, California-based diversified healthcare REIT that owns and operates private-pay facilities such as life science centers, medical offices and continuing care retirement communities. Although it has properties across the country, most are in the San Francisco, San Diego and Boston areas.&nbsp;</p>
<p>Healthpeak's IPO was created in 1985, and it was added to the S&amp;P 500 in 2008. It owns 477 properties totaling over 50 million square feet with over 2,500 tenants, worth over $20 billion.</p>
<p>On March 1, Healthpeak officially merged with Physicians Realty Trust in an all-stock-for-stock transaction.&nbsp;</p>
<p>On April 1, Bank of America Securities analyst Dennerlein upgraded Healthpeak Properties from Underperform to Buy, while raising the price target 38.8% from $18 to $25.&nbsp;</p>
<p>Healthpeak will announce its first-quarter 2024 earnings on April 26.</p>
<h2 class="wp-block-heading"><strong>Explore Opportunities Beyond REITs</strong></h2>
<p>While publicly traded REITs offer a convenient way to invest in real estate, we believe that some of the most compelling opportunities lie in the private market. Benzinga's <a href="https://www.benzinga.com/go/real-estate-screener">real estate offering screener</a> features a curated selection of private market real estate offerings from trusted platforms with a track record of strong returns.</p>
<p>Whether you&#8217;re an accredited or non-accredited investor, you can filter opportunities based on your investment criteria, including minimum investment, property type and target return. These offerings provide a unique chance to diversify your portfolio and tap into potential high-yield investments that are not available on public exchanges.</p>
<p><a href="https://www.benzinga.com/go/real-estate-screener">Browse offerings</a></p>
<p><strong>Latest Private Market Offerings</strong></p>
<ul>
<li><a href="https://www.benzinga.com/alternative-investments/listing/qoz-fund-iii"><strong>QOZ Fund III</strong></a><strong>: </strong>Realize massive tax benefits by investing in a portfolio of multifamily development projects with long-term growth potential located in designated Opportunity Zones.</li>
<li><a href="https://www.benzinga.com/alternative-investments/listing/incomeplus-fund"><strong>Income Plus Fund:</strong></a> A private real estate fund for investors seeking passive income and appreciation &#8211; Target net annual return of 9% &#8211; 11%.&nbsp;</li>
<li><a href="https://www.benzinga.com/alternative-investments/listing/gold-leaf-farming-lp"><strong>Golden Leaf Farming LP</strong></a>: Top-tier almond and pistachio farms with a target cash yield of 13.8%</li>
</ul>
<p>Discover these and other exclusive real estate investment opportunities on Benzinga's offering screener. Dive into the private market and uncover the potential for substantial returns beyond the public REIT market.</p>


<p>Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) has been analyzed by 3 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Healthpeak Properties, presenting an average target of $21.67, a high estimate of $25.00, and a low estimate of $19.00. Surpassing the previous average price target of $18.00, the current average has increased by 20.39%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711976453_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Healthpeak Properties among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Healthpeak Properties. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Healthpeak Properties's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Healthpeak Properties's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Healthpeak Properties analyst ratings.</strong></a></p>
<h2>All You Need to Know About Healthpeak Properties</h2>
<p>Healthpeak owns a diversified healthcare portfolio of approximately 459 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.</p>
<h3>Unraveling the Financial Story of Healthpeak Properties</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Healthpeak Properties displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>5.56%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>12.79%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Healthpeak Properties's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.11%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Healthpeak Properties's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.45%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.12</strong>, Healthpeak Properties adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Healthpeak Properties: Insights From 3 Financial Analysts

<p>B of A Securities  analyst Joshua Dennerlein   upgrades Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) from Underperform to Buy and raises the price target from $18 to $25.</p>


B of A Securities Upgrades Healthpeak Properties to Buy, Raises Price Target to $25

<p>Wells Fargo  analyst Connor Siversky   reinstates Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Equal-Weight and announces $19 price target.</p>


Wells Fargo Reinstates Equal-Weight on Healthpeak Properties, Announces $19 Price Target

<p>RBC Capital  analyst Michael Carroll   reinstates Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and announces $21 price target.</p>


RBC Capital Reinstates Outperform on Healthpeak Properties, Announces $21 Price Target

<p>S&amp;P 500 constituent Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEAK#NYSE">PEAK</a>) is acquiring Physicians Realty Trust in a deal expected to be completed soon pending final conditions. Post-merger, Healthpeak Properties will have a symbol change from PEAK to DOC.&nbsp;</p>


American Homes 4 Rent To Replace Physicians Realty Trust In S&P MidCap 400 Effective Prior To The Opening Of Trading On March 1

<p>Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEAK#NYSE">PEAK</a>) (&quot;Healthpeak&quot;) today announced that, in connection with its and Healthpeak OP, LLC&#39;s (&quot;Healthpeak OP&quot;) previously announced consent solicitation and offers to guarantee for Physicians Realty L.P. (a consolidated subsidiary of Physicians Realty Trust (NYSE:&nbsp;<a href="https://www.benzinga.com/stock/doc#NYSE">DOC</a>) (&quot;Physicians Realty Trust&quot; or &quot;DOC&quot;)) senior notes related to Healthpeak&#39;s agreement to merge with Physicians Realty Trust (the &quot;Merger&quot;), it has received the required consents from the holders of the outstanding Physicians Realty L.P. senior notes listed below (collectively, the &quot;DOC Notes&quot;) to adopt the proposed amendments to each of the supplemental indentures to the Senior Indenture (each, an &quot;Indenture&quot;) governing such DOC Notes.</p>


Offerings

Healthpeak Properties, Inc. and Healthpeak OP, LLC Complete Consent Solicitation And Offers To Guarantee and Receive Required Consents To Amend Physicians Realty L.P. Indentures

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Real estate investment trusts or REIT stocks to buy can offer investors reassurances during tricky economic cycles. In addition, they can position you for a more favorable outcome if you anticipate a shift in monetary policy.</p>



<p>Generally speaking, REITs are sensitive to interest rate fluctuations. Further, under a low interest rate environment, this market category can be attractive because the underlying enterprises generally pay robust passive income. Under high interest rates, government bonds begin competing with private enterprises, posing challenges.</p>



<p>While it&rsquo;s not a sure thing, the Federal Reserve may consider a more dovish policy. If so, passive income providers can become much more attractive. Below are REIT stocks to buy.</p>



<h2>Healthpeak Properties (DOC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/healthcare_staffing1600-300x169.png" alt="Medicine and healthcare concept - team or group of doctors and nurses"><div>Source: Supavadee butradee / Shutterstock.com</div></div><p>Based in Denver, Colorado, <strong>Healthpeak Properties</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/doc-stock-quote/"><strong>DOC</strong></a>) is one of the REIT stocks to buy in the <a href="https://finance.yahoo.com/quote/DOC/profile">healthcare facilities space</a>. This includes investments related to senior housing, life science and medical offices. Fundamentally, DOC is attractive because while so many headlines focus on attaining wealth, it doesn&rsquo;t mean anything without health. In other words, people largely will do anything to stay alive.</p>



<p>As a result, healthcare related ideas present an opportunistic profile and DOC stock is no different. Financially, though, Healthpeak comes off as a mixed bag. Between the second quarter of last year to Q1 2024, the average earnings surprise came out to 6% below parity.</p>



<p>The good news is that the REIT is posting net income, to the tune of $193.06 million in the trailing 12 months (<a href="https://investorplace.com/stock-quotes/ttm-stock-quote/"><strong>TTM</strong></a>). However, the not so great news is that occasionally, Healthpeak can miss the mark widely. Still, it&rsquo;s important to note that the current quarterly revenue growth rate (year-over-year) stands at 15.4%.</p>



<p>&nbsp;For fiscal 2024, analysts anticipate 19.9% upside in sales to $2.61 billion. Combined with a forward yield of 6.3%, DOC should be on your radar for REIT stocks to buy.</p>



<h2>Park Hotels &amp; Resorts (PK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/hotels-1600-300x169.jpg" alt="Woman standing in hotel room with luggage looking at the view. Hotel stocks."><div>Source: Boyloso / Shutterstock</div></div><p>Based in Tysons, Virginia, <strong>Park Hotels &amp; Resorts</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/pk-stock-quote/"><strong>PK</strong></a>) specializes &ndash; obviously &ndash; in the lodgings space. <a href="https://finance.yahoo.com/quote/PK/profile">Per its corporate profile</a>, Park is one of the largest REIT stocks to buy in the ecosystem. The underlying enterprise features a diverse portfolio of market-leading hotels and resorts commanding significant value. Its portfolio consists of 43 premium-branded establishments covering over 26,000 rooms.</p>



<p>Fundamentally, PK could benefit from the heightened sense of travel prioritization; that&rsquo;s basically an offshoot of the revenge travel phenomenon. In terms of earnings performances, Park is hit or miss. That said, it&rsquo;s been hitting more often than not in the past four quarters since Q1. The average surprise comes out to 48.75%.</p>



<p>In the TTM period, net income landed at $90 million on revenue of $2.7 billion. Currently, Park is experiencing a quarterly revenue decline. However, fiscal 2025 is projected to be a decent year, with consensus sales rising to $2.75 billion. Further, the high-side target goes up to $3.02 billion.</p>



<p>Combined with a forward dividend yield of 6.29%, PK makes an attractive package for REIT stocks to buy.</p>



<h2>Realty Income (O)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/realty1600-300x169.jpg" alt="realty income logo highlighted by a magnifying glass on a web browser"><div>Source: Shutterstock</div></div><p>A no-brainer in terms of REIT stocks to buy, <strong>Realty Income</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/o-stock-quote/"><strong>O</strong></a>) focuses on the retail space. <a href="https://finance.yahoo.com/quote/O/profile">Per its public profile</a>, Realty invests in free-standing, single-tenant commercial properties in the U.S., U.K. and Spain. It&rsquo;s tremendously attractive because the tenants of the various properties cover a range of necessities, from home improvement retailers to pharmacies.</p>



<p>Stated differently, no matter what&rsquo;s going on in the economy, people will need access to certain goods and services. With Realty housing these areas of needs, it enjoys consistent income. To be fair, its performance relative to analysts&rsquo; expectations have been lumpy. However, in the TTM period, the REIT posted net income of $776.99 million on revenue of $4.4 billion.</p>



<p>Notably, the quarterly revenue growth rate presently stands at 33.3%. For fiscal 2024, experts believe earnings will rise to $1.43 per share on sales of $5.04 billion. That&rsquo;s up 13.5% on the bottom line and up 23.5% on the top.</p>



<p>Finally, Realty pays a forward annual dividend of 5.9% and guess what? It pays out monthly. You&rsquo;ll want to keep close tabs on O stock.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/3-reits-to-buy-now-may-2024/">3 REITs to Buy Now: May 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 REITs to Buy Now: May 2024

Picking A Winner In Healthcare REITs

Real estate stocks gain after inflation report even as major market averages lose

JRI: Get Real Assets At A Big Discount And Collect 14% Yield

State Of REIT Nation: Waiting At The Bottom

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Impressively, <strong>BlackRock</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/blk-stock-quote/"><strong>BLK</strong></a>) was founded in 1988 in New York. So, this iconic company is likely younger than many people reading this article. However, impressively, BlackRock&rsquo;s total assets under management <a href="https://www.statista.com/statistics/891292/assets-under-management-blackrock/" target="_blank">crossed $10 trillion back in 2021</a>. This number has stayed relatively stable since. But this sort of growth has caused many to envision BlackRock as some sort of enigmatic entity that controls everything. </p>



<p>That&rsquo;s generally a far-fetched view of the company, but I do think BlackRock&rsquo;s buying activity is important for other reasons. For retail investors, it may be worth considering which stocks this company is buying. Doing so may allow certain investors to replicate parts of BlackRock&rsquo;s broader investing strategy.</p>



<p>Larger institutional investors tend to have a significant resource advantage, and BlackRock has certainly advanced this idea. The company has been behind many notable changes in the stock market, such as ESG investing. As such, following in BlackRock&rsquo;s footsteps could lead to outsized gains relative to those investing in passive index funds, if you believe the institutional money manager&rsquo;s process works. </p>



<p>Here are seven <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> to consider I think fits the bill. That&rsquo;s because each of these seven companies are ones <a href="https://whalewisdom.com/filer/blackrock-inc" target="_blank">Blackrock bought more of in the first quarter</a>.</p>



<h2>Microsoft (MSFT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/shutterstock_698745022-compressor-300x169.jpg" alt="Image of corporate building with Microsoft logo above the entrance."><div>Source: NYCStock / Shutterstock.com</div></div><p><strong>Microsoft</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/"><strong>MSFT</strong></a>) doesn&rsquo;t really need an introduction. I believe Microsoft&rsquo;s strong Q3 results highlight why it remains one of the most compelling long-term investments in the tech sector, if not the best. The company reported <a href="https://www.tradingview.com/news/invezz:56372191c094b:0-microsoft-reports-another-quarter-of-solid-growth/" target="_blank">record revenue of $61.86 billion</a> this past quarter, up an impressive 17% year-over-year. These results were driven by the continued strength of its Microsoft Cloud platform, which surpassed $35 billion in sales.</p>



<p>Microsoft is firing on all cylinders. Its Azure cloud infrastructure is taking market share, and the company is making significant strides in advancing the artificial intelligence revolution via partnerships with <strong>OpenAI</strong> and others.</p>



<p>The white-collar sector already can&rsquo;t get enough of Microsoft&rsquo;s productivity products, and with Microsoft Copilot adding more appeal, I expect these AI tailwinds to further propel Microsoft&rsquo;s growth. While the stock isn&rsquo;t cheap at 32-times forward earnings, Microsoft&rsquo;s indispensable role in the global economy and its fortress-like competitive advantages make it a core holding for any growth portfolio. It&rsquo;s no surprise that BlackRock is betting big on Microsoft&rsquo;s long-term potential.</p>



<h2>Confluent (CFLT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/big-data-visual-300x169.png" alt="An image of different overlaid data charts"><div>Source: solarseven/Shutterstock</div></div><p><strong>Confluent</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cflt-stock-quote/"><strong>CFLT</strong></a>) provides a data streaming platform based on Apache Kafka. The company is riding powerful secular growth tailwinds in the real-time data processing, cloud adoption, and digital transformation areas of the economy, which should continue to see strong demand for years to come. While currently unprofitable, Confluent&rsquo;s Q1 results show investors that this is a company that&rsquo;s rapidly moving towards sustained profitability.</p>



<p>Confluent reported <a href="https://www.investors.com/news/technology/confluent-stock-jumps-on-sales-earnings-beat-for-data-software-player/" target="_blank">25% revenue growth this past quarter,</a> or a top line number of $217 million. This number beat estimates, with the company&rsquo;s high-growth Confluent Cloud product now comprising the majority of its sales. Analysts now expect <a href="https://seekingalpha.com/symbol/CFLT/earnings/estimates" target="_blank">around 20%-25% top-line growth to continue</a> for the foreseeable future. Importantly, Confluent also posted an impressive improvement in its operating margins to 22%, the fourth straight quarter of such gains. Analysts expect full-year 2024 profitability with accelerating earnings growth ahead.</p>



<p>With elite institutions like BlackRock buying the stock, Confluent appears well-positioned to emerge as one of the most dominant software players of this decade. This positioning has many analysts seeing juicy upside for CFLT stock.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/06/chart-27.png"><img width="1226" height="455" src="https://investorplace.com/wp-content/uploads/2024/06/chart-27.png" alt="Confluent upside"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><h2>Nutanix (NTNX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/cloud1600d-300x169.jpg" alt=""><div>Source: Shutterstock</div></div><p><strong>Nutanix</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntnx-stock-quote/"><strong>NTNX</strong></a>) provides cloud computing software for businesses to manage their data centers and IT infrastructure. The company is also riding several powerful mega trends that could propel the stock significantly higher in the years ahead. In its latest quarter, Nutanix grew <a href="https://ir.nutanix.com/news-releases/news-release-details/nutanix-reports-third-quarter-fiscal-2024-financial-results" target="_blank">revenue 16.9% year-over-year to $525 million</a>, while annual recurring revenue (<span>ARR</span>) surged 24% to $1.82 billion. Management highlighted steady demand as organizations prioritize digital transformation and infrastructure modernization to optimize costs. I&rsquo;m of the view NTNX stock is owns that should recover alongside its improving earnings per share numbers.<span><a href="https://investorplace.com/stock-quotes/-stock-quote/"></a></span></p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/06/chart-28.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/06/chart-28.png" alt="Nutanix EPS"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>Recently, Nutanix scored a major win with a Fortune 50 financials company looking to automate its database deployment using Nutanix&rsquo;s cloud platform. Another Fortune 500 consumer goods provider decided to standardize its back-end on Nutanix&rsquo;s software stack and swap out a competitor&rsquo;s footprint. </p>



<p>I believe Nutanix&rsquo;s best-in-class platform positions the company at the center of the hybrid multi-cloud and data center automation revolutions. With shares already up 81.5% over the past year, I wouldn&rsquo;t be surprised to see this momentum continue as more large enterprises turn to Nutanix to maximize their IT efficiency in this digital age.</p>



<h2>Pure Storage (PSTG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/storage-facility-1600-300x169.jpg" alt="A photo of a storage facility hallway."><div>Source: Kostsov / Shutterstock.com</div></div><p>Notice a trend here? I definitely do. Blackrock is betting massively on data center companies. <strong>Pure Storage</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/pstg-stock-quote/"><strong>PSTG</strong></a>) provides data storage hardware and software solutions. The company is also among those on this list that delivered strong Q1 results, with <a href="https://www.nasdaq.com/articles/pure-storage-pstg-reports-q1-earnings-what-key-metrics-have-say" target="_blank">revenue growing 17.7% year-over-year to $693 million</a>, beating estimates by $13 million. Pure Storage is seeing early success in capturing AI-related opportunities across high-performance computing, enterprise inference engines and upgrading enterprise storage to eliminate data silos. I believe the hyper-growth upside AI provides is a major tailwind that could propel PSTG stock much higher. And notably, subscriptions have been driving most of the growth here:</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/06/chart-29.png"><img width="1226" height="741" src="https://investorplace.com/wp-content/uploads/2024/06/chart-29.png" alt="Pure Storage subscriptions revenue"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>The company&rsquo;s management team recently highlighted a key platform win with a managed service provider specializing in AI infrastructure, demonstrating Pure Storage&rsquo;s differentiated offerings. The company&rsquo;s unified Purity platform simplifies data management across on-premises and cloud environments, which is crucial for enterprises looking to use AI. As more companies jump aboard, and the company continues to diversify its client base, investors stand to benefit from increased cash flow stability.</p>



<p>With PSTG shares already up 83% over the past year, some may think this rally may be overdone. However, I think this is a stock that could see its momentum continue, as long as the company sustains its robust growth trajectory.</p>



<h2>Amazon (AMZN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/amzn-stock-10-300x169.jpg" alt="Amazon LOGO ON THE SIDE OF A BUILDING."><div>Source: Sundry Photography / Shutterstock.com</div></div><p><strong>Amazon</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/"><strong>AMZN</strong></a>) dominates the high-growth e-commerce and cloud computing sectors. I believe this tech titan is morphing into an AI and data powerhouse, resulting in a stock that continues to make new highs. In Q1, Amazon delivered an impressive <a href="https://www.investing.com/news/stock-market-news/earnings-call-amazon-reports-strong-q1-with-focus-on-ai-and-aws-growth-93CH-3411459" target="_blank">13% revenue growth (ex-FX) to $143.3 billion</a>. The company&rsquo;s operating income also skyrocketed 221% to $15.3 billion, as Amazon&rsquo;s efficiency efforts are clearly paying off.</p>



<p>In the world of mega-cap cloud players, AWS remains the undisputed leader. Amazon Cloud Services now provide the lion&rsquo;s share of Amazon&rsquo;s profits. And with generative AI tools already used by over 100,000 sellers, Amazon is harnessing cutting-edge tech to enhance its ecosystem.</p>



<p>I expect key tailwinds like the continued shift to online shopping, AWS&rsquo;s dominance, and emerging AI innovations to provide long-term capital appreciation to patient investors. While consumers are cautious (trading down in this uncertain economy), Amazon&rsquo;s everyday low prices and ultra-fast delivery are clearly resonating with a loyal clientele.</p>



<p>As long as the macro picture improves (or at least cooperates), I believe Amazon will command a premium valuation &ndash; maybe even a higher multiple. In my view, this is an evergreen stock to buy and hold long-term.</p>



<h2>Pinterest (PINS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/PINS1600-300x169.jpg" alt="the pinterest (PINS stock) logo on a mobile phone held by a woman"><div>Source: Nopparat Khokthong / Shutterstock.com</div></div><p><strong>Pinterest</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/pins-stock-quote/"><strong>PINS</strong></a>) operates a visual discovery engine for finding ideas like recipes, home and style inspiration, and more. While some may consider Pinterest a fading social media platform, the company&rsquo;s latest results paint a different picture. In Q1, Pinterest <a href="https://www.morningstar.com/news/marketwatch/20240430811/pinterests-stock-soars-17-on-big-revenue-and-profit-beat-500-million-monthly-active-users" target="_blank">achieved its highest user and revenue growth since 2021</a>, with global monthly active users (MAUs) surpassing 500 million for the first time. Specifically, this metric grew to 518 million monthly users, up 12% year-over-year. Revenue also impressed, growing 23% to $740 million, nearly doubling the growth rate from the previous quarter.</p>



<p>I believe several mega trends could propel Pinterest higher in the coming years. The continued shift to digital advertising plays to Pinterest&rsquo;s strengths, as its visual format and user intent make it an attractive platform for brands. The company&rsquo;s focus on AI-driven improvements to content relevance and curation is deepening user engagement. And with Pinterest&rsquo;s earnings per share and revenue expected to double over the next five years, Pinterest&rsquo;s growth story seems far from over.</p>



<p>While primarily popular with women, Pinterest&rsquo;s expanding user base and reaccelerating ad revenue suggest it may be an under-appreciated growth opportunity that&rsquo;s just hitting its stride. BlackRock is in, and I am too.</p>



<h2>Healthpeak Properties (DOC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600c-300x169.jpg" alt="healthcare stocks: doctors posing. retirement stocks. Healthcare stocks"><div>Source: Shutterstock</div></div><p><strong>Healthpeak Properties</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/doc-stock-quote/"><strong>DOC</strong></a>) is a healthcare REIT that owns and develops real estate serving the healthcare industry. While the stock has struggled to regain its 2013 peak, I believe there are compelling reasons BlackRock is still interested in this company. In Q1, Healthpeak delivered <a href="https://seekingalpha.com/article/4686783-healthpeak-properties-inc-doc-q1-2024-earnings-call-transcript" target="_blank">revenue of $600.81 million</a>, beating estimates and translating into impressive 15.65% year-over-year growth. Management also raised full-year 2024 earnings guidance by 2 cents at its midpoint.</p>



<p>Healthpeak&rsquo;s recent merger seems to be a major positive catalyst, with the integration exceeding expectations. Healthpeak has already successfully internalized its property management business, acquiring 17 million square feet of profitable real estate to add to its growing portfolio. With plans to pursue additional deals, I believe significant growth is certainly possible from here. Over the next year, the company&rsquo;s EBIT should inflect higher, pushing DOC stock up.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/06/chart-30.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/06/chart-30.png" alt="Helathpeak EPS estimates"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>And while investors wait for DOC stock to recover, Healthpeak&rsquo;s 6.2% dividend yield should provide more than enough incentive to keep holding. I don&rsquo;t think this is a real estate company that&rsquo;s posted to slash its dividend anytime soon, as the company&rsquo;s payout ratio and dividend yield metrics are reasonable (and have stabilized quite a bit).</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/06/chart-31.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/06/chart-31.png" alt="DOC dividends"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>Analysts also expect robust <a href="https://seekingalpha.com/symbol/DOC/earnings/estimates" target="_blank">22.4% sales growth this year and 5%-plus annual earnings per share growth</a> starting next year. Along with the other names on this list, I can see why BlackRock likes this name. </p>



<p><em>On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/7-growth-stocks-blackrock-is-buying-and-you-should-too/">7 Growth Stocks BlackRock Is Buying (and You Should Too)</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Growth Stocks BlackRock Is Buying (and You Should Too)

Mizuho Securities analyst Vikram Malhotra maintained a Buy rating on Healthpeak Properties (DOC – Research Report) on June 13 and set a price targe...

Mizuho Securities Reaffirms Their Buy Rating on Healthpeak Properties (DOC)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The average dividend yield of the 503 stocks in the <strong>S&amp;P 500 </strong>is <a href="https://www.multpl.com/s-p-500-dividend-yield/table/by-year">1.3%.</a> That makes it difficult to find high-yield <a href="https://investorplace.com/stock-types/dividend-stocks/">dividend stocks</a> to buy.&nbsp;</p>



<p>According to Finviz.com, there are <a href="https://finviz.com/screener.ashx?v=111&amp;f=fa_div_o6,idx_sp500">10 stocks</a> in the index, yielding 6% or more. Not all 10 are bargains. Some, like <strong>Walgreens Boots Alliance </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/wba-stock-quote/"><strong>WBA</strong></a></span>), might be considered &ldquo;value traps&rdquo; by many investors even after falling 42% in 2024.&nbsp;</p>



<p>Nonetheless, of the 9 remaining stocks yielding 6%, I don&rsquo;t think there&rsquo;s any doubt at least three are bargains despite such a high yield.&nbsp;</p>



<p>If you expand the search to all U.S.-listed stocks yielding 6% or more and a market capitalization over $2 billion, the field widens to <a href="https://finviz.com/screener.ashx?v=111&amp;f=cap_midover,fa_div_o6">141.</a> It is from here I will select three high-yield dividend stocks to buy.&nbsp;</p>



<p>To make things interesting, I&rsquo;ll pick one from the S&amp;P 500, one from the <strong>Dow Jones Industrial Average</strong> and one from the <strong>Russell 2000</strong>.&nbsp;</p>



<h2>Healthpeak Properties (DOC)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/04/healthcaremsn-300x165.jpg" alt="Amazon"><div>Source: Shutterstock</div></div><p><strong>Healthpeak Properties </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/doc-stock-quote/"><strong>DOC</strong></a></span>) is a healthcare-focused REIT (real estate investment trust) based in Denver. Its annual dividend rate of <a href="https://ir.healthpeak.com/news/news-details/2024/Healthpeak-Properties-Reports-First-Quarter-2024-Results-and-Declares-Quarterly-Cash-Dividend-on-Common-Stock/default.aspx">$1.20</a> yields 6.2%.</p>



<p>On March 1, the REIT <a href="https://ir.healthpeak.com/news/news-details/2024/Healthpeak-Properties-Closes-Merger-with-Physicians-Realty-Trust/default.aspx">completed</a> its all-stock merger of equals with Physicians Realty Trust. The transaction valued the combined companies at $21 billion. Shareholders received <a href="https://www.sec.gov/Archives/edgar/data/765880/000110465923112345/tm2329359d3_ex99-1.htm">0.674 Healthpeak shares</a> per Physicians Realty Trust share.</p>



<p>Physicians brought to the table an internal property management platform and established industry relationships. It expects the merged entity to generate up to $60 million in annual synergies by the end of 2025.&nbsp;</p>



<p>The combined REIT has 52 million square feet of healthcare space, including one of the largest outpatient medical portfolios with 40 million in high-growth markets and affiliated with leading hospitals and health systems. Its top three markets are San Francisco, Boston and Dallas, with 13.7 million square feet.</p>



<p>Its <a href="https://ir.healthpeak.com/files/doc_financials/2024/q1/Healthpeak-Supplemental-Report-03-31-2024.pdf">balance sheet</a> is top-notch, with just $1.7 billion of its long-term debt maturing before 2028. The weighted average interest rate of its $8.73 billion in total debt (not including lease liabilities) is a reasonable 3.8%.&nbsp;</p>



<p>On the same day it closed its merger, the company obtained a new $750 million, 5-year unsecured term loan with a fixed interest rate of 4.5% for the entire period. Its net debt is just 5.2x its adjusted EBITDA.&nbsp;</p>



<h2>Verizon Communications (VZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/vz-stock-9-300x169.jpg" alt="Verizon Wireless sign and trademark logo."><div>Source: Ken Wolter / Shutterstock.com</div></div><p>Admittedly, I prefer <strong>T-Mobile U.S. </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tmus-stock-quote/"><strong>TMUS</strong></a></span>) to either <strong>Verizon Communications </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/vz-stock-quote/"><strong>VZ</strong></a></span>) or <strong>AT&amp;T </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/t-stock-quote/"><strong>T</strong></a></span>). However, of the two biggest, Verizon is a better buy than AT&amp;T.&nbsp;</p>



<p>In May, I argued that Verizon&rsquo;s free cash flow growth made it a <a href="https://investorplace.com/2024/05/3-stocks-to-buy-from-one-of-americas-top-dividend-etfs/">good dividend stock to buy</a> from the <strong>Schwab U.S. Dividend Equity ETF </strong>(NYSEARCA:<span><a href="https://investorplace.com/stock-quotes/schd-stock-quote/"><strong>SCHD</strong></a></span>). While analysts don&rsquo;t love it, it trades at a low 8.4x its 2025 earnings per share estimate of $4.71.</p>



<p>Verizon&rsquo;s quarterly dividend amounts to an annual payment of $2.66 a share, a yield of 6.8%. Income investors ought to like that.&nbsp;</p>



<p>One quarter into 2024, Verizon&rsquo;s wireless revenues were up <a href="https://www.verizon.com/about/sites/default/files/1Q2-2024-Earnings-News-Release.pdf">3.3%,</a> to $19.5 billion, while its free cash flow in the first quarter was $2.7 billion, 17% higher than a year earlier. Its trailing 12-month free cash flow is <a href="https://www.morningstar.com/stocks/xnys/vz/financials">$13.44 billion.</a></p>



<p>On a price-to-sales basis, its market cap is 1.24x sales, lower than its five-year average of 1.48x. Its forward price-to-earnings ratio is 8.62x, less than its five-year average of 9.58x.</p>



<p>While it&rsquo;s not nearly as cheap as it was last October, the high yield more than makes up for it.</p>



<h2>Artisan Partners Asset Management (APAM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/apam-stock-1-300x169.jpg" alt="Artisan Partners (APAM) logo"><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p>I&rsquo;ve recommended Wisconsin-based <strong>Artisan Partners Asset Management</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/apam-stock-quote/"><strong>APAM</strong></a></span>) in the past.&nbsp;</p>



<p>In January 2022, I included it on my <a href="https://investorplace.com/2022/01/10-best-stocks-to-buy-for-your-income-generating-portfolio-axp-deo-bp-stor-cwh-rio-gbdc-apam/">dividend-income ladder</a> from 1% to 10% yields. It was 10.3% back then. A part of that yield was because of the 31-cent special dividend it paid out in 2021.&nbsp;</p>



<p>Year-to-date, it&rsquo;s paid out <a href="https://www.morningstar.com/stocks/xnys/apam/dividends">$1.63</a> in dividends &mdash; February payment of 68 cents, February special dividend of 34 cents and May dividend of 61 cents &mdash; with approximately $1.26 to be paid out over the final two regular payments of the year. Based on $2.44 in annual dividends and a share price of $40, it&rsquo;s currently yielding 6.33%.&nbsp;</p>



<p>One of the things I like about Artisan is that nearly <a href="https://www.apam.com/static-files/4fb22c79-9ad7-4ff3-9177-bfe93a0f4d1f">13%</a> of its voting shares are controlled by directors and executive management. They are, as they say, &ldquo;Eating their own cooking.&rdquo;</p>



<p>As of May 31, it had assets under management (AUM) of <a href="https://www.apam.com/static-files/3a3c1be2-650a-4131-9884-5a038f918de0">$158.6 billion,</a> with its funds business accounting for 49% and separate accounts for 51%. Its Q1 2024 <a href="https://www.apam.com/static-files/1b7fdde0-f47d-4d98-9a41-456fc1d01fbb">adjusted operating income</a> was $81.6 million, 16.6% higher than a year earlier, on $264.4 million in revenue, 12.8% higher year over year.&nbsp;</p>



<p>Whenever it trades around $30, load up the truck and grab yourself an enhanced dividend yield.</p>



<p><em>On the date of publication, Will Ashworth did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a></em></p>
<div><p>Will Ashworth has written about investments full-time since 2008. Publications where he&rsquo;s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/doc-vz-apam-6-dividend-yielding-bargains-to-buy-now/">DOC, VZ, APAM: 6% Dividend-Yielding Bargains to Buy Now</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

DOC, VZ, APAM: 6% Dividend-Yielding Bargains to Buy Now

Real estate stocks edge down, while major market averages gain marginally

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Down by one run in the bottom of the ninth, you, as the batter, have several options. That&rsquo;s especially the case with the bases loaded and one out on the board. Arguably, a consensus of baseball experts will agree that there is one correct choice: this action item is the equivalent of high <a href="https://investorplace.com/stock-types/dividend-stocks/">dividend stocks</a>.</p>



<p>Now, if you&rsquo;re the San Diego Padres, you&rsquo;re going to be tempted to do something stupid, such as swinging on the first pitch. That&rsquo;s the equivalent of eschewing high dividend stocks and instead acquiring super-risky high growth plays. In that scenario, if you swing and don&rsquo;t contact the ball just right, you can end up hitting into a double play. That ends the game.</p>



<p>No, what you do to secure the run and, at least, end the inning on level ground. You work the opposing pitcher and let him &ldquo;score&rdquo; a run &ndash; for your team. Of course, this tactic carries risks because there&rsquo;s a good chance you can let a pitch you like passively sail by.</p>



<p>But sometimes, you just need a run. And that&rsquo;s what high dividend stocks potentially give you: a chance to win. With that, below are compelling ideas to consider.</p>



<h2>Devon Energy (DVN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/dvn_devon_1600-300x169.png" alt="An image of a hand holding a smartphone displaying the Devon Energy Corporation logo in front of a computer screen"><div>Source: T. Schneider / Shutterstock.com</div></div><p>Based in Oklahoma City, Oklahoma, <strong>Devon Energy</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/dvn-stock-quote/"><strong>DVN</strong></a>) falls under the oil and gas exploration and production sphere. To be fair, the hydrocarbon ecosystem has been under pressure for various reasons. One of them is elevated borrowing costs that have applied pressure on pricing. Nevertheless, geopolitical dynamics could shift in a cynically favorable manner. If so, you may want exposure to high dividend stocks in the upstream energy sector.</p>



<p>It must be said, however, that Devon isn&rsquo;t peaches and cream. Yes, it has consistently beaten its bottom-line earnings targets in the past four quarters. Also, during the trailing 12 months (TTM), the company did post net income of $3.36 billion. However, in terms of quarterly earnings and revenue growth, Devon is presently down on a year-over-year basis.</p>



<p>Further, projections for fiscal 2024 aren&rsquo;t pretty. Earnings per share may slip 6.13% to $5.36. Revenue may fall slightly to $15.25 billion. However, a geopolitical flashpoint that threatens global hydrocarbon supply chains could easily boost demand in the upstream sector.</p>



<p>Let&rsquo;s not forget why we&rsquo;re here. Devon offers a <a href="https://www.dividend.com/stocks/energy/oil-gas-coal/exploration-production/dvn-devon-energy/">forward dividend yield of 1.86%</a>. That&rsquo;s not something to ignore.</p>



<h2>Qifu Technology (QFIN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/fintech-1-300x169.jpg" alt='A hand lingers over a bright blue tech wheel that says "fintech." Bargain fintech stocks for June'><div>Source: Wright Studio / Shutterstock.com</div></div><p>Moving into the riskier sphere of high dividend stocks, we&rsquo;re going to talk about China&rsquo;s <strong>Qifu Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/qfin-stock-quote/"><strong>QFIN</strong></a>). Falling under the financial services sector, Qifu is involved in credit services. That&rsquo;s a bit of a mixed bag when you consider some of the frailties of the post-pandemic global economy. Nevertheless, it&rsquo;s also intriguing because of the company&rsquo;s ties to the Chinese commercial machinery.</p>



<p>Financial technology (fintech) firms are booming and so, the Chinese market should be no different. Prospective investors may be encouraged with Qifu&rsquo;s performance consistency. Between the second quarter of 2023 to Q1 2024, the company&rsquo;s average EPS reached just under $1. This performance translated to an earnings surprise of 4.58%.</p>



<p>During the TTM period, Qifu posted net income of $4.52 billion or earnings of $3.82 per share. Revenue in the period reached $16.84 billion. Further, the most recent quarterly sales growth rate (YOY) stands at 15.4%. Therefore, the rather modest expectations for fiscal 2024 should see an upgrade.</p>



<p>In the meantime, speculators can enjoy the fintech firm&rsquo;s <a href="https://www.dividend.com/stocks/financials/specialty-finance/consumer-finance/qfin-qifu-technology-inc-adr/">5.46% forward annual dividend</a> yield. It&rsquo;s one of the high dividend stocks to consider.</p>



<h2>LyondellBasell Industries (LYB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/lyb_1600-300x169.jpg" alt="A LyondellBasell production plant in Wesseling, Germany is seen at dusk."><div>Source: Flagmania / Shutterstock.com</div></div><p>Based in Houston, Texas, <strong>LyondellBasell Industries</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/lyb-stock-quote/"><strong>LYB</strong></a>) operates within the specialty chemicals industry. It specializes in material sciences, delivering critical assets to various industries. Its processing technologies also serve multiple sectors, including food packaging, home furnishings, automotive components and paints and coating applications. Granted, it&rsquo;s not the most exciting idea among high yield dividend stocks. It is, however, extremely pertinent.</p>



<p>Ultimately, that&rsquo;s what you&rsquo;re looking for as a passive-income investor: pertinence. Again, we&rsquo;re not necessarily interested in hitting a grand slam (though that would be nice). Instead, we&rsquo;re putting runs on the board, one at a time. LyondellBasell, despite incurring some misses in recent earnings reports, is a solid long-term candidate because of the underlying relevance.</p>



<p>During the TTM period, the company posted net income of $2.11 billion or $6.48 per share. Revenue reached $40.78 billion. For fiscal 2024, it sees a slight dip in EPS while sales might rise 1% to $41.56 billion. That&rsquo;s not great though the most optimistic analyst is calling for revenue of $47.49 billion.</p>



<p>Either way, LyondellBasell offers a forward yield of 5.63%. That makes it one of the high dividend stocks to consider.</p>



<h2>Healthpeak Properties (DOC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/doctor_medicine_dna_1600-300x169.jpg" alt="Various graphical representations of medical imagery are shown in front of a doctor using a tablet computer. DNA stock"><div>Source: Shutterstock / PopTika</div></div><p>Structured as a real estate investment trust or REIT, <strong>Healthpeak Properties</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/doc-stock-quote/"><strong>DOC</strong></a>) is a fully integrated enterprise that focuses on the healthcare sector. <a href="https://stockanalysis.com/stocks/doc/company/">Per its public profile</a>, Healthpeak owns, operates and develops high-quality real estate for healthcare discovery and delivery. Since the sector enjoys a permanently relevant narrative, DOC makes a compelling argument for high dividend stocks.</p>



<p>To be clear, I&rsquo;m not suggesting that Healthpeak is permanently relevant and thus faces no downside risk: that&rsquo;s not the case at all. Rather, the concept of medical professionals caring for their patients is effectively a forever market. Financially, it must be said that Healthpeak is rather hit or miss. When it&rsquo;s cooking, it&rsquo;s cooking. When it&rsquo;s not, you can tell.</p>



<p>During the TTM period, the REIT posted net income of $193.06 million or 35 cents per share. Revenue in the period reached $2.26 billion. Now, the intriguing aspect is that while analysts project a sizable drop in EPS to 35 cents in fiscal 2024, they&rsquo;re simultaneously projecting sales of $2.61 billion. If so, that would be up 19.8% from the prior year.</p>



<p>It&rsquo;s possible, then, that investors can enjoy growth and passive income. Right now, the company offers a forward yield of 6.24%.</p>



<h2>Apple Hospitality (APLE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/hotels-1600-300x169.jpg" alt="Woman standing in hotel room with luggage looking at the view. Hotel stocks."><div>Source: Boyloso / Shutterstock</div></div><p>Headquartered in Richmond, Virginia, <strong>Apple Hospitality</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/aple-stock-quote/"><strong>APLE</strong></a>) is also structured as a REIT. It falls under the hotel and metal segment, as its name suggests. As of the end of Q1 2024, Apple owned 224 hotels with a total of nearly 30,000 individual guest rooms. These rooms are spread across 37 states and the District of Columbia.</p>



<p>Fundamentally, Apple may benefit from travel prioritization. When Covid-19 regulations started fading, the phenomenon of revenge travel shot into the mainstream consciousness. Nowadays, the acute need to travel has diminished, especially amid rising inflation and interest rates. Still, consumer data shows that people are prioritizing experiential-based events. That could lead to downwind benefits for APLE stock.</p>



<p>In the TTM period, Apple posted net income of $198.62 million or 85 cents per share. Revenue in the cycle hit $1.36 billion. Notably, covering experts forecast that fiscal 2024 EPS could rise 19.5% to reach 92 cents. On the top line, sales may rise 7.3% to hit $1.44 billion.</p>



<p>For passive income, Apple offers a forward dividend yield of 6.58%. That makes it a tempting proposition for high dividend stocks.</p>



<h2>Gaming and Leisure (GLPI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/casino1600-300x169.jpg" alt="a room of slot machines in a casino to represent gambling stocks"><div>Source: Shutterstock</div></div><p>Based in Pennsylvania, <strong>Gaming and Leisure</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/glpi-stock-quote/"><strong>GLPI</strong></a>) is another REIT, this time focusing on the casino gaming sector. <a href="https://stockanalysis.com/stocks/glpi/company/">Per its corporate profile</a>, Gaming and Leisure is engaged in the business of acquiring, financing and owning real estate property to be leased to gaming operators. Fundamentally, the business appears compelling due to the aforementioned travel prioritization effect.</p>



<p>While folks may no longer use the term revenge travel, the underlying concept is still alive. People have been cooped up for a long time during Covid. And that reality may have inspired a sense that there&rsquo;s more to life than merely punching a clock. To be fair, it&rsquo;s a higher-risk play because the REIT has been hit or miss with its most recent earnings disclosures.</p>



<p>Still, the company could make a comeback, especially if travel interests focus on the domestic realm. During the TTM period, net income reached just under $725 million or $2.71 per share. Revenue landed at $1.46 billion. For fiscal 2024, analysts see a modest rise in EPS to $2.86. On the top line, sales could enjoy a 5.1% lift to $1.51 billion.</p>



<p>Lastly, the company offers a forward dividend yield of 6.85%. It&rsquo;s a tempting candidate for high dividend stocks.</p>



<h2>Vector Group (VGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/04/tobacco-stocks-300x169.jpg" alt="a pile of cigarettes"><div>Source: Shutterstock</div></div><p>Headquartered in Miami, Florida, <strong>Vector Group</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/vgr-stock-quote/"><strong>VGR</strong></a>) falls under the consumer defensive sector, technically speaking. However, investors will zero in on the tobacco specialty. Of course, the business is controversial. It also runs relevancy concerns given how much anti-tobacco organizations have successfully broadcasted the health risks associated with the industry.</p>



<p>So, why bother discussing VGR stock? Frankly, even with global smoking prevalence rates down, many people continue to enjoy the practice. Moreover, Vector has a subsidiary called Zoom E-Cigs, which, as you might guess, sells e-cigarettes. Featuring a relatively cleaner format than the traditional variety, e-cigarettes (or vaporizers) have catapulted in popularity.</p>



<p>Admittedly, Vector has seen some rough waters in recent earnings disclosures. During the TTM period, the company posted net income of $178.63 million or $1.16 per share. Revenue hit $940.42 million. Still, for fiscal 2024, analysts do see a 10.3% lift in EPS to $1.28.</p>



<p>In terms of passive income, Vector offers a gargantuan 7.2%. It&rsquo;s super risky given the underlying controversial industry. Still, it&rsquo;s one of the most tempting high dividend stocks to consider.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>



<p></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/7-dividend-stock-dynamos-to-upgrade-your-income-game/">7 Dividend Stock Dynamos to Upgrade Your Income Game</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Dividend Stock Dynamos to Upgrade Your Income Game

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

AHTR

APAM

APLE

BBRE

BLDG

BXMT

CBRE

CFLT

CHCT

CSGP

CUBE

DFAR

EQIX

FREL

GLPI

GQRE

HAUS

HAUZ

HOMZ

IFGL

INDS

INVH

JPRE

KBWY

MORT

MSFT

NAIL

NETL

NTNX

NURE

PFFR

PINS

PLDGP

PPTY

PSTG

QFIN

RDOG

REET

REGCO

REGCP

RIET

ROOF

RSPR

SBAC

SCHD

SCHH

SPRE

SRET

SRVR

STWD

TMUS

USRT

VICI

VIOO

VRAI

XLRE

Press Releases

Healthpeak Properties Stockholders and Physicians Realty Trust Shareholders Approve Merger

Healthpeak Properties, Inc. and Healthpeak OP, LLC Complete Consent Solicitation and Offers to Guarantee and Receive Required Consents to Amend Physicians Realty L.P. Indentures

American Homes 4 Rent Set to Join S&P MidCap 400

Healthpeak Properties Announces First Quarter 2024 Earnings Release Date and Conference Call Details

Healthpeak Properties Reports First Quarter 2024 Results and Declares Quarterly Cash Dividend on Common Stock

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Physicians Realty Trust and Encourages Investors to Contact the Firm

Healthpeak Properties Announces Joint Venture Wind-Down

Healthpeak Properties to Present at Nareit's REITweek 2024 Investor Conference

Healthpeak Properties Publishes Its 13th Annual Corporate Impact Report

Healthpeak Properties Announces Second Quarter 2024 Earnings Release Date and Conference Call Details

SPGI

American Healthcare REIT, Inc. Common Stock

American Healthcares


Chris JacobsHouse (R-NY)	$1K - $15K	Purchase	Jan 20, 2023	Dec 12, 2022	House
Chris JacobsHouse (R-NY)	$1K - $15K	Sale	Dec 12, 2022	Nov 08, 2022	House
Chris JacobsHouse (R-NY)	$1K - $15K	Sale	Sep 09, 2022	Jul 18, 2022	House
Chris JacobsHouse (R-NY)	$15K - $50K	Purchase	Jul 28, 2022	Jun 21, 2022	House

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government Trades

Healthpeak Properties Inc

top performing DOC trades